Completed PHASE1 INTERVENTIONAL 2-arm NCT02544217

A Dose-escalating Clinical Trial With KH176

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176

Sponsor: Khondrion BV

Conditions LHON Leigh Syndrome MELAS Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation Mitochondrial Disease

Updated 8 times since 2017 Last updated: Oct 15, 2021 Started: May 31, 2015 Primary completion: Sep 30, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on LHON and Leigh Syndrome, this trial is completed. The trial is conducted by Khondrion BV and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Feb 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Feb 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Dec 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Dec 2020 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Khondrion BV
University Ghent

Data source: Khondrion BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ghent, Belgium